Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

If Maggie O'Neil can't find a match among family members, she'll have to turn to a global nonprofit that connects volunteer ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...

The following is a summary of “Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to ...